U.S. Regulatory Verification & Supplier Qualification
A procurement-focused guide to matching an exact insulin syringe SKU with the responsible FDA roles, applicable 510(k), registration and listing records, QMSR controls, labeling, UDI, import responsibilities and postmarket evidence.
Scope: This is an educational procurement resource, not legal, regulatory, clinical or patient-specific advice. Requirements depend on the device, labeling, intended use, establishment activities, import route and transaction. Verify current FDA records and obtain qualified regulatory advice for a specific market-access or private-label decision.
Quick answer
What Are the FDA Requirements for Insulin Syringe Suppliers?
FDA requirements for insulin syringe suppliers depend on what each company actually does. A finished-device manufacturer, specification developer, contract manufacturer, foreign manufacturer, initial importer, repacker/relabeler and ordinary distributor do not carry identical obligations. For a typical human-use insulin syringe, the buyer should verify the applicable Class II piston-syringe pathway, the responsible 510(k) holder, current establishment registration and device listing, QMSR controls, U.S. labeling, UDI/GUDID data where applicable, import roles and postmarket responsibilities.
The practical approval unit is the exact quoted SKU. A company name, registration number, ISO 13485 certificate or 510(k) number is not sufficient unless it can be reconciled with the legal manufacturer, manufacturing site, brand, REF, concentration scale, capacity, graduation, gauge × length, design, labeling and pack hierarchy being purchased.
Executive summary
Key Takeaways for U.S. Buyers
- “Supplier” is a commercial term, not one FDA role. Determine each party’s regulated activities before asking what requirements apply.
- Insulin syringes are typically Class II piston syringes. FDA’s FMF classification entry identifies 21 CFR 880.5860, Class II and submission type 510(k).[1]
- 510(k), registration and listing are different records. FDA does not issue medical-device registration certificates, and registration/listing does not mean approval or clearance.[3]
- QMSR is now the current U.S. quality-system framework. It became effective February 2, 2026 and incorporates ISO 13485:2016 by reference into amended 21 CFR Part 820.[7]
- Public records must be matched to the commercial item. Verify the exact REF, manufacturer, labeler, design, labeling, identifiers and pack—not merely a product family name.
- Current safety and enforcement information matters. Review recalls, warning letters, import alerts and FDA’s plastic-syringe safety communication before approval and periodically afterward.
1. FDA Does Not Regulate “Supplier” as One Single Role
A seller may call itself an insulin syringe supplier while performing only distribution, or it may also design the device, own the brand, contract the manufacturing, relabel the package, import the goods and handle complaints. FDA obligations attach to these activities and legal roles—not to the marketing word “supplier.”
Start the qualification with a role map. Ask who owns the finished-device specifications, who holds the applicable 510(k), where the device is physically manufactured, who performs sterilization and packaging, whose name appears as manufacturer or labeler, who submits UDI data, who is the foreign establishment’s U.S. Agent, and who acts as the U.S. initial importer. The same organization may hold several roles, but the responsibilities should still be stated separately.
Buyer rule: Do not ask only, “Is your company FDA registered?” Ask, “What FDA role does each company perform for this exact REF, and which record or controlled document supports that role?”
2. How Insulin Syringes Are Classified in the United States
FDA’s product-classification database identifies the piston syringe under product code FMF as a Class II device regulated under 21 CFR 880.5860, with submission type 510(k) and no GMP exemption.[1] FDA’s piston-syringe guidance states that the generic type can include insulin syringes and may include a hypodermic needle attached to the barrel.[11]
That classification entry is a starting point, not a substitute for reviewing the offered device. A safety feature, different intended use, novel technological characteristic, separate needle configuration or another change can affect the applicable product code, review questions or submission scope. The supplier should identify the actual product code and regulation for the quoted item; the buyer should not infer them from appearance.
| Field | Typical piston-syringe entry | Buyer action |
|---|---|---|
| Device type | Piston syringe | Confirm the offered product is within this device type |
| Product code | FMF | Match the code in the applicable 510(k) and listing |
| Regulation | 21 CFR 880.5860 | Check the current eCFR text and any limitations |
| Class | Class II | Do not describe it as FDA approved solely because it is listed |
| Premarket pathway | 510(k) | Verify whether a cleared submission applies to the exact device |
3. When Is a 510(k) Required?
FDA explains that a person introducing a non-exempt device to the U.S. market generally must submit a 510(k) before marketing. The submission demonstrates substantial equivalence to a legally marketed predicate; it is not a product “approval” under the PMA pathway.[2]
The submitting party depends on the business arrangement. FDA states that a specification developer generally submits the 510(k), while a contract manufacturer making a device to another party’s specifications is not required to submit solely because of that contract-manufacturing role. A repacker or relabeler may need a new 510(k) if its changes significantly affect labeling or device condition, and a foreign manufacturer introducing the product may also be a required submitter.[2]
A previously cleared syringe does not make every future change automatically acceptable. Changes to intended use, design, materials, needle, sterilization, packaging, manufacturing site or performance may require documented regulatory assessment and, depending on significance, a new 510(k). For private-label programs, define who makes that assessment and who prevents commercial artwork or SKU changes from outrunning the cleared and listed device.
4. 510(k) Clearance vs Registration vs Device Listing
These terms are often collapsed into an inaccurate “FDA certificate.” Keep them separate in every supplier file.
| Record | What it supports | What it does not prove |
|---|---|---|
| 510(k) clearance | FDA found the submitted device substantially equivalent for the cleared scope | It does not automatically cover every brand, REF, size, needle, label or later modification |
| Establishment registration | An establishment registered for one or more activities for the current registration period | It is not FDA approval, certification or endorsement of the facility or product |
| Device listing | A responsible establishment associated a device with its registration information | It does not replace required premarket clearance or prove every quoted REF is in scope |
| ISO 13485 certificate | A certification body assessed the stated QMS scope against ISO 13485 | It is not an FDA certificate, 510(k) clearance or evidence that the exact SKU is listed |
FDA explicitly says it does not certify devices or issue registration certificates to medical-device facilities, and that a registration/listing entry does not denote approval, clearance or authorization.[3] A buyer should therefore retain database evidence and source documents—not a decorative certificate created by a third party.
5. Manufacturer, Specification Developer, Labeler and Distributor Responsibilities
The following matrix is a purchasing aid, not a complete legal determination. One firm can occupy several rows, and details depend on the actual activities.
| Role or activity | Typical FDA focus | Buyer evidence |
|---|---|---|
| Finished-device manufacturer | Applicable premarket authorization, QMSR, registration/listing, labeling, UDI and postmarket controls | Legal name, site, 510(k) mapping, listing, QMS scope, label and complaint contacts |
| Specification developer | Controls finished-device specifications and generally submits the 510(k) for the device it introduces | 510(k) holder, design responsibility, contract manufacturer and change-control allocation |
| Contract manufacturer | Manufactures to another party’s specifications; registration/listing and QMS obligations can apply, but it does not submit solely because it is the contractor | Actual site, registered role, QMS scope, quality agreement and approved processes |
| Repacker / relabeler | Registration/listing, labeling controls and possible 510(k) impact if changes are significant | Artwork authority, package process, listing relationship and regulatory change assessment |
| UDI labeler | Assigns the device identifier and submits required GUDID data where the UDI rule applies | Labeler identity, DI/GTIN, GUDID record and controlled package levels |
| Ordinary distributor | Distribution alone generally does not make it the 510(k) submitter; other duties arise if it relabels, imports or performs additional regulated activities | Authorized source, traceability, complaint forwarding, recall communication and no-substitution control |
For a full commercial evaluation after the regulatory gates are passed, use Tonmit’s insulin syringe supplier qualification framework. That separate guide addresses cost, service, inventory and performance without duplicating the FDA evidence chain developed here.
6. Foreign Manufacturer, U.S. Agent and Initial Importer Requirements
A foreign establishment engaged in manufacturing or processing a device imported into the United States must identify a U.S. Agent. The U.S. Agent assists FDA communications and scheduling; this role should not be confused with the initial importer’s operational obligations.[5]
FDA defines an initial importer as an importer that furthers marketing from a foreign manufacturer toward final delivery or sale without repackaging or otherwise changing the package or labeling. FDA states that the initial importer must have a staffed physical U.S. address, register, identify imported manufacturers and carry applicable responsibilities, including medical-device reporting.[4][14]
Before relying on imported supply, determine whether the product or firm is subject to an import alert and whether entry data consistently identify the correct manufacturer and device. FDA notes that foreign manufacturers and imported devices must comply with applicable U.S. requirements at importation.[6]
7. What Changed Under the FDA QMSR in 2026?
The Quality Management System Regulation became effective on February 2, 2026. It amended 21 CFR Part 820 and incorporates ISO 13485:2016 by reference, with additional FDA-specific provisions.[7] Supplier pages written for the former Quality System Regulation should not present old section 820.50 as though it remains the standalone current purchasing-controls clause.
For an insulin syringe program, the practical buyer questions remain familiar: Are outsourced processes selected and controlled according to risk? Are product specifications, suppliers, sterilizers and packaging providers approved? Are receiving and release records controlled? Are nonconformities, complaints, corrective actions and changes connected to the device history? The legal framework and inspection approach, however, should be described using the current QMSR.
What an ISO 13485 certificate can—and cannot—do
A current certificate with relevant activities and sites can support a supplier review. It does not make the device “FDA certified,” does not prove the exact REF is cleared or listed, and does not exempt the manufacturer from FDA inspection. FDA’s QMSR FAQ also explains that FDA does not issue ISO 13485 certificates through its inspections.[8]
8. Labeling, UDI and GUDID Verification
The buyer should compare the current U.S. label and package with the approved purchasing specification. At minimum, confirm product identity, concentration scale, nominal capacity, graduations, needle gauge and length, sterile and single-use status, manufacturer or labeler information, REF, lot, expiration, storage conditions, warnings and package quantity as applicable.
FDA’s UDI system is intended to identify devices through distribution and use. Where UDI requirements apply, the device identifier identifies the labeler and specific version or model, and production identifiers may include lot, serial number, expiration date or manufacturing date when those data appear on the label.[9] GUDID is the FDA-administered reference catalog for device identifier records; it does not contain every production lot.[10]
For private label, determine the UDI labeler, issuing agency, DI/GTIN for each package level, GUDID submission owner and update process before artwork approval. Tonmit’s private-label insulin syringe guide explains why brand ownership, specification control, labeling and postmarket roles must be mapped before launch.
9. Performance, Biocompatibility, Sterilization and Shelf-Life Evidence
Regulatory records identify the market pathway; technical evidence supports the actual product. FDA’s piston-syringe guidance addresses device description, materials, performance, sterilization and labeling considerations.[11] FDA also partially recognizes ISO 8537:2016 for sterile, single-use insulin syringes, with or without needles.[12] Conformity to a standard can support a submission or qualification package, but it is not automatic U.S. market authorization.
| Evidence area | What to request | Fields to reconcile |
|---|---|---|
| Device performance | Applicable test summary, declaration or controlled report index | Capacity, scale, graduation, leakage, dead space, plunger and needle performance |
| Biocompatibility | Evaluation or test summary appropriate to contact type and duration | Materials, colorants, lubricant, needle and exact product family |
| Sterilization | Method, validation status, routine release controls and residuals support as applicable | Product family, load, site, sterilizer and packaging configuration |
| Sterile barrier | Package integrity, seal, distribution and aging support | Primary package, sealing site, transit configuration and label claim |
| Shelf life | Current aging rationale or study summary and labeled expiry | REF, materials, packaging, sterilization and change history |
| Needle specification | Applicable dimensional and performance records | Gauge, length, wall, bond, tip and fixed/removable design |
Buyers can request SKU-specific documentation support after identifying the manufacturer, exact REF, target market and intended review. Access may be staged because full reports can contain controlled or confidential information; a document index and applicable summaries should still permit the buyer to understand what evidence exists and what product it covers.
10. How to Match an FDA Record to the Exact Quoted SKU
A 510(k) database result may show an applicant, device name, product code and decision date, while the commercial quote uses a distributor item number or private-label REF. The buyer needs a controlled bridge between those records.
Quoted SKU → seller item → brand / trade name → legal manufacturer → actual manufacturing site
Product identity → REF → concentration scale → capacity → graduation → gauge × length → fixed/removable or safety design
U.S. evidence → product code → applicable 510(k) → registration/listing → UDI/GUDID where applicable → current label
Received supply → box/case hierarchy → lot → expiration → receiving record → inventory location → outbound traceability
- Freeze the quotation: legal manufacturer, brand, REF and complete syringe specification.
- Open the 510(k) record and summary; compare applicant, trade/device name, product code, intended use and described models.
- Obtain a manufacturer-controlled mapping statement when the public summary does not list the commercial REF.
- Check current registration/listing relationships for the relevant establishments and roles.
- Compare the U.S. label, IFU and GUDID data where applicable with the quoted and sampled product.
- Record unresolved differences and prohibit substitution until the evidence chain is complete.
Use the insulin syringe size and marking guide to distinguish 0.3, 0.5 and 1 mL SKUs, and the U-40 vs U-100 guide to control concentration-scale mismatch. A 31G needle or 0.5 mL barrel alone is never a complete regulatory or purchasing identity.
11. Current FDA Safety Context for Plastic Syringes Made in China
As of this article’s regulatory review on August 6, 2026, FDA’s safety communication on plastic syringes made in China remains an active procurement consideration. The communication, last updated August 16, 2024, states that FDA continued evaluating quality and performance issues such as leaks and breakage and recommended using non-China-manufactured syringes when possible.[13]
FDA specifically recommended immediate transition away from plastic syringes made by Jiangsu Caina Medical Co., Ltd., Jiangsu Shenli Medical Production Co., Ltd. and Shanghai Kindly Enterprise Development Group Co., Ltd., unless use was absolutely necessary during transition. For other plastic syringes made in China, FDA recommended checking manufacturing location, using alternatives when possible and closely monitoring for problems.[13]
Do not overstate—or ignore—the FDA communication
- It does not say that every syringe manufactured in China is banned.
- A 510(k) clearance does not replace verification of the current manufacturing site, commercial REF, import status and quality history.
- Supplier qualification should include current warning letters, recalls and import-alert checks by legal manufacturer and site.
- Because the situation can change, record the date of every public-database review and repeat it before major orders.
12. Complaints, MDR, Recalls, Corrections and Changes
FDA’s Medical Device Reporting regulation makes manufacturers, importers and device user facilities mandatory reporters for specified events; ordinary buyers and distributors should know how complaints are escalated to the responsible parties.[14] A supplier should identify who evaluates reportability, who communicates with FDA and how the seller transfers samples, event data and lot information.
Recall readiness requires more than a generic policy. The buyer should be able to select a lot, locate all on-hand inventory, identify affected outbound orders, quarantine remaining stock and document customer notification. FDA’s correction and removal framework includes 21 CFR Part 806 reporting responsibilities for manufacturers and importers in applicable situations.[15]
| Process | Required supplier answer | Buyer record |
|---|---|---|
| Complaint intake | Named routine and urgent contacts with acknowledgment targets | Complaint form, contact list and escalation time |
| MDR evaluation | Responsible manufacturer/importer and data-transfer process | Role allocation and event-information checklist |
| Recall / field action | Lot/customer identification and notification process | Mock-recall result and reconciliation time |
| Corrections / removals | Who assesses Part 806 reporting and coordinates action | Quality agreement and action records |
| Change control | Advance notice for device, material, site, sterilization, pack, label and identifier changes | Notice period, approver and requalification trigger |
13. Insulin Syringe Supplier Documentation Checklist
Use this checklist before samples, first order and recurring approval. Mark each item applicable, not applicable with rationale, received, reviewed, expired or unresolved.
- Legal manufacturer, specification developer, contract manufacturer, sterilizer, labeler and manufacturing-site identities.
- Seller, foreign exporter, U.S. Agent and initial importer roles where applicable.
- Exact REF, brand/trade name, concentration scale, capacity, graduation, gauge × length and design type.
- Product code, regulation number and applicable 510(k), plus controlled REF-to-submission mapping.
- Current establishment registration and device-listing information for relevant roles.
- Current U.S. label, IFU and package artwork at each commercial level.
- UDI/GTIN and GUDID information where applicable, including the responsible labeler.
- Current ISO 13485 certificate and scope as supporting—not substitutive—evidence.
- Applicable performance, biocompatibility, sterilization, sterile-barrier and shelf-life support.
- Units/box, boxes/case, cases/pallet, barcode levels, country of origin, lot and expiration formats.
- Complaint, MDR escalation, recall, correction/removal, return and nonconformance contacts.
- Change-notification agreement covering manufacturer, site, design, material, needle, sterilization, packaging, label and identifiers.
- Current recall, warning-letter, import-alert and safety-communication review dated by the evaluator.
14. Five-Step FDA Database Verification Workflow
Public databases are most useful when searched in a controlled sequence and documented with the query date, legal name and model terms.
Confirm device type, product code, regulation, class and premarket pathway.
Review applicant, trade name, product code, decision and public summary.
Review current registration/listing and role relationships.
Compare labeler, DI/model and GUDID attributes where applicable.
Search recalls, warning letters, MAUDE and import alerts in context.
Absence of a result is not automatically a clean bill of health: names change, private-label terms may differ, public summaries may omit commercial REFs and databases have reporting limits. Conversely, a complaint or warning letter should be read for the named firm, product, date, status and corrective context before drawing a conclusion. FDA notes that import-alert databases are updated in real time.[16]
15. Regulatory and Documentation Red Flags
Pause or reject the quotation when the supplier:
- markets an unofficial “FDA registration certificate” as product clearance;
- uses “FDA approved,” “FDA certified” or “100% FDA compliant” as a blanket syringe claim;
- withholds the legal manufacturer, actual site, labeler or exact REF;
- provides a 510(k) that names another product without a controlled mapping explanation;
- cannot reconcile scale, capacity, graduation, gauge, length, design or package with the U.S. label;
- provides an ISO 13485 certificate whose holder, site or scope does not match the supply chain;
- cannot name the initial importer or explain complaint and MDR escalation for imported products;
- does not address current FDA syringe safety communications, warning letters or import alerts;
- permits substitution or site, material, sterilization, label or packaging changes without notice;
- cannot connect shipped lot and expiration data to receiving and customer records.
16. Copyable FDA Compliance Section for an Insulin Syringe RFQ
Send the same fields to every candidate. Require line-by-line exceptions instead of a one-word “compliant” response.
Product identity: Quote the legal manufacturer, actual manufacturing site, brand/trade name, exact REF, concentration scale, capacity, graduation, needle gauge × length, fixed/removable or safety design, individual package, units/box and boxes/case.
FDA role map: Identify the finished-device manufacturer, specification developer, contract manufacturer, sterilizer, repacker/relabeler, UDI labeler, foreign exporter, U.S. Agent and initial importer as applicable.
Classification: State the device type, FDA product code, class and regulation number for the exact quoted product.
Premarket record: Provide the applicable 510(k) number and a controlled explanation mapping the exact REF, design and current U.S. label to the cleared device.
Registration and listing: Provide current searchable establishment and listing information for each applicable FDA role; do not submit an unofficial registration certificate as evidence of clearance.
QMS: Provide current ISO 13485 certification and scope plus available information showing that relevant manufacturing, outsourced processes, release, complaints and changes operate under the current QMSR framework.
Labeling and UDI: Provide current U.S. label/IFU, UDI/GTIN and GUDID information where applicable, labeler identity and barcode/package hierarchy.
Technical evidence: Identify applicable performance, biocompatibility, sterilization, packaging and shelf-life records for the exact product family and sites.
Import and postmarket: Identify the initial importer, entry-data responsibility, complaint/MDR escalation, recall/correction/removal contacts and lot-traceability process.
Current compliance screen: Disclose applicable recalls, warning letters, import alerts, FDA safety communications and unresolved regulatory actions involving the manufacturer, site or quoted product.
Change control: No change to manufacturer, site, REF, design, material, needle, sterilization, package, label, UDI or applicable market record without prior written notice and buyer review.
Commercial request: State sample availability, MOQ, price basis, inventory source, lot, expiration, minimum remaining shelf life, lead time, destination and delivery terms.
After the compliance gate is passed, buyers can review wholesale insulin syringe options, plan case quantities and landed cost, and confirm U.S. warehouse-supported fulfillment by exact REF, lot, expiration and destination.
Buyer FAQ: Insulin Syringe FDA Requirements
Are insulin syringes Class II medical devices?
FDA’s FMF piston-syringe classification entry identifies the device as Class II under 21 CFR 880.5860. Verify that the quoted insulin syringe falls within that classification and whether another product code or additional consideration applies to its design.
Do insulin syringes require 510(k) clearance?
The typical FMF piston-syringe pathway lists submission type 510(k). A person introducing a non-exempt device generally needs an applicable cleared submission before marketing. The responsible submitter and scope depend on the device and business roles.
Should a supplier say “FDA approved” or “FDA cleared”?
For a device marketed through the 510(k) pathway, “cleared” is generally the accurate term for the device within the submission scope. “FDA approved” should not be used to describe registration, listing or a 510(k) clearance.
Is FDA registration the same as 510(k) clearance?
No. Establishment registration identifies a facility and activities; device listing associates a device with an establishment; 510(k) clearance is a premarket substantial-equivalence decision. FDA says registration and listing do not denote approval, clearance or authorization.
Does FDA issue medical-device registration certificates?
No. FDA explicitly states that it does not issue registration certificates to medical-device facilities and does not certify registered facilities or listed devices.
Can one 510(k) cover several insulin syringe sizes?
A cleared submission may include a family of configurations, but coverage is submission-specific. Compare the public summary and controlled manufacturer mapping with the exact concentration scale, capacity, graduation, gauge, length, design and label being quoted.
Is ISO 13485 certification enough for U.S. sales?
No. It can support QMS review, but it does not replace an applicable 510(k), registration/listing, labeling, UDI, import or postmarket requirements. FDA does not issue ISO 13485 certificates through its inspections.
What changed under QMSR in 2026?
QMSR became effective February 2, 2026, amended 21 CFR Part 820 and incorporates ISO 13485:2016 by reference with FDA-specific provisions. Supplier and audit language should now reflect this current framework.
What should a buyer verify in GUDID?
Where UDI requirements apply, compare the device identifier record with the labeler, brand, model/version, package level and other identifying attributes. Production lots are controlled through label and transaction records rather than treated as GUDID device-identifier entries.
What is the difference between a U.S. Agent and an initial importer?
The U.S. Agent supports communications between FDA and a foreign establishment. The initial importer furthers marketing toward the ultimate U.S. customer without repackaging or relabeling and has its own registration, manufacturer-association and postmarket responsibilities.
Does private labeling require a new 510(k)?
Not automatically, but the result depends on who controls the specifications and whether labeling or other operations significantly affect the device. Define the specification developer, repacker/relabeler, UDI labeler and change-assessment responsibilities before launch.
How should buyers handle FDA’s China syringe safety communication?
Check the actual manufacturing location and named manufacturer, review current FDA recommendations, warning letters, recalls and import alerts, and document the review date. Do not convert the communication into an unsupported claim that every China-manufactured syringe is prohibited.
What documents should be requested before ordering?
Request a role map, exact specification, 510(k) mapping, current registration/listing, U.S. label/IFU, UDI/GUDID data where applicable, QMS scope, technical evidence index, pack hierarchy, lot/shelf-life controls, import roles, postmarket contacts and change-notification terms.
Can U.S. warehouse stock replace regulatory verification?
No. Domestic inventory can shorten the fulfillment path, but the buyer must still verify the exact REF, manufacturer, applicable U.S. records, labeling, lot, expiration and postmarket traceability.
Conclusion: Approve a Traceable Regulatory Evidence Chain
The most useful way to apply insulin syringe FDA requirements is to move from broad claims to a documented chain: regulated roles, device classification, applicable 510(k), registration/listing, current QMSR controls, U.S. labeling and UDI, importer responsibilities, technical support and postmarket readiness—all mapped to the exact quoted REF.
A supplier should not pass because it can produce a registration number, ISO certificate or 510(k) PDF. It should pass when the buyer can reconcile those records with the product, parties, sites, labels, identifiers and lots that will actually enter inventory, and when unresolved changes cannot be substituted without review.
SKU-specific procurement support
Request an Insulin Syringe Documentation Review
Send the legal manufacturer or preferred brand, exact REF or target specification, quantity, destination, private-label scope and required document checklist. Tonmit can organize available product, packaging, documentation and fulfillment information for transaction-specific buyer review.
Final product eligibility, documentation, labeling, inventory, pricing and delivery are confirmed by exact SKU and transaction.References
- U.S. Food and Drug Administration. Product Classification: Piston Syringe, Product Code FMF. Accessed August 6, 2026.
- U.S. Food and Drug Administration. Premarket Notification 510(k). Accessed August 6, 2026.
- U.S. Food and Drug Administration. Important Reminders about Registration and Listing. Accessed August 6, 2026.
- U.S. Food and Drug Administration. Who Must Register, List and Pay the Fee. Accessed August 6, 2026.
- U.S. Food and Drug Administration. U.S. Agents. Accessed August 6, 2026.
- U.S. Food and Drug Administration. Importing Medical Devices and Radiation-Emitting Electronic Products into the U.S.. Accessed August 6, 2026.
- U.S. Food and Drug Administration. Quality Management System Regulation (QMSR). Effective February 2, 2026.
- U.S. Food and Drug Administration. Quality Management System Regulation: Frequently Asked Questions. Accessed August 6, 2026.
- U.S. Food and Drug Administration. UDI Basics. Accessed August 6, 2026.
- U.S. Food and Drug Administration. Global Unique Device Identification Database (GUDID). Accessed August 6, 2026.
- U.S. Food and Drug Administration. Guidance on 510(k) Submissions for Piston Syringes. Accessed August 6, 2026.
- U.S. Food and Drug Administration. Recognized Consensus Standard: ISO 8537:2016. Partial recognition; accessed August 6, 2026.
- U.S. Food and Drug Administration. Evaluating Plastic Syringes Made in China for Potential Device Failures: FDA Safety Communication. Updated August 16, 2024; accessed August 6, 2026.
- U.S. Food and Drug Administration. Mandatory Reporting Requirements: Manufacturers, Importers and Device User Facilities. Accessed August 6, 2026.
- U.S. Food and Drug Administration. Recalls, Corrections and Removals (Devices). Accessed August 6, 2026.
- U.S. Food and Drug Administration. Import Alerts. Accessed August 6, 2026.
